Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance
Date:8/7/2009

hin the United States and Canada is (888) 208-1812. Participants outside the United States and Canada should call (719) 325-2339. A replay of the conference call will be available for two weeks following the call and can be accessed by dialing (888) 203-1112 from within the United States and Canada or (719) 457-0820 from outside the United States and Canada. The replay ID number is 6093247.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebte
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...rMadeinSupportofFeedingAmerica,sSNAPOutreachEffort...edingAmerica,thenation,slargesthunger-relieforgani...ofAmericaCharitableFoundationtosupportFeedingAmeri...lementalNutritionAssistanceProgram(SNAP),formerlyn...edingAmericafoodbanksimproveaccessandprovidepre-sc...
(Date:11/25/2009)... essential to normal human development - the Wnt/W... (EGFR) pathways - interact in ways that can promo... from The University of Texas M. D. Anderson Cance... Cell . , This newly characterized interaction i...ate with invasive cancer - activation of EGFR, ele...
(Date:11/25/2009)...n R. Kaplan, MD, FACP, a former Board Chair and on...ecame Los Angeles Biomedical Research Institute at...onored by the American College of Physicians for h...At its April 22, 2010 meeting in Toronto, the Amer... with the Ralph O. Claypoole Sr. Memorial Award fo...
(Date:11/25/2009)...at UT Southwestern Medical Center soon will begin ...ing in patients with upper spinal-cord injuries or...pendently. , UT Southwestern University Hospita... and one of 25 in the country currently equipped t...acing System. , The device is designed to give p...
(Date:11/25/2009)...ial function plays in insulin production , ...ondrial damage causes people with type 2 diabetes ...uld lead to new treatments, U.S. researchers say. ...vity. , The researchers found that when insulin...d to circulating insulin, it triggers a "molecular...
Breaking Medicine News(10 mins):Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 2Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 3Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:1 of LA BioMed's founders to be honored 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2
...sue alive, benefits other organs, study finds , ...ared to CPR alone, adding extracorporeal life supp...diac arrest, says a study by researchers at the Na...point blood travels through the catheter via a pum...
...premier research company in San Jose, releases sev...report provides a comprehensive insight into the p...luencing the market, growth drivers, and major cha... San Jose, CA (PRWEB) July 9, 20...
...ation that would cut $268 million,from Medicare Ad... Seniors across Minnesota,are speaking out against...n,legislation being considered in the U.S. Senate....are private,fee-for-service plans can operate, adv...
...dical care for the uninsured, human,services, and ...y 9 Blue Cross and Blue Shield,of Illinois (BCBSI...organizations in Illinois. In line with its missio... mostly on,community-based organizations that prov...
...experts at the University of Alabama at Birmingham...y Genomics-Based Medicine Project. The project is ...d academic centers working to improve treatment an...earch site in the Southeast. UAB is one of four co...
...r Engines, and Nominate Now at ..., one of the most trusted brands,for indigestion a...rch for,one lucky fan to serve as the Grand Marsha...cgi-bin/prnh/20080709/AQW525 ), "TUMS, and the al...
Other Medicine News:Health News:ELS Plus CPR Boosts Blood Flow After Cardiac Arrest 2Health News:Global Industry Analysts' Releases a Series of Medical Market Research Reports 2Health News:Global Industry Analysts' Releases a Series of Medical Market Research Reports 3Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 3Health News:UAB joins elite brain cancer research group 2Health News:TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500 2
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--QuestDiagnosticsIncorp...nostictesting,informationandservices,announcedthat...lthcareConferenceinNewYorkCity.Thepresentationissc...nTime. ,, Duringtheconference,thecompanywillrea...%,operatingincometoexceed18%ofrevenues,anddilutede...
(Date:11/24/2009)....J.andNEWYORK,Nov.24/PRNewswire/-- EisaiInc.andPf...tration(FDA)hasacceptedforreviewEisai,sNewDrugAppl...lHClextendedrelease)tabletsforthetreatmentofmodera...formulationcontains23mgofdonepezilHClinanextendedr...owsforgradualreleaseofthedrug.TheNDAisbasedonahead...
(Date:11/24/2009).../PRNewswire/--Accumetrics,Inc.,aprivately-helddeve...trapidandeasy-to-usediagnosticsystemformeasuringan....g.Plavix®andaspirin),announcedtodaythatTimot....Tibbitts,ChiefFinancialOfficerofAccumetrics,willb...affrayHealthCareConferencebeingheldinNewYorkCityon...
Breaking Medicine Technology:Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Novel Facebook Application Aims to Prevent Cervical Cancer 59302 1Novel Facebook Application Aims to Prevent Cervical Cancer 59302 2California Walnuts Popular Smart Menus Program Getting Smarter 59297 1California Walnuts Popular Smart Menus Program Getting Smarter 59297 2California Walnuts Popular Smart Menus Program Getting Smarter 59297 3University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 5397 1University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 5397 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 5397 3
...YORK, Dec. 13 - The Michael J. Fox,Foundation for ...n for,research toward therapies to alleviate Parki...rders. The funding is to be awarded under a new,in... Parkinson,s Disease,made possible by generous lea...orth America), affiliates of Merck KGaA, Darmstadt...
... Suggest Continued Improvement in Motor Function a...oday presented,long-term follow-up data from a Pha...h advanced Parkinson,s disease. CERE-120 uses gene...urin to the major area of,neurodegeneration that o...s. Long-term follow up assessments at 18 and 24 mo...
Other Medicine Technology:MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders 2MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders 3MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders 4Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 2Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 3Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 4
BLF21 Single Channel
Oxyflo 2000
Multi Dop X4
Multi Dop L1
Medicine Products: